NeuroDerm’s Shares Double Following Parkinson’s Study Results

January 1, 2014 | The Israeli company listed on NASDAQ NeuroDerm saw its share price doubled following the announcement of results from a Parkinson’s drug trial. According to the company, a mid-stage study showed that giving patients a higher dose of its Parkinson’s drug could allow them to avoid surgery in certain cases. NeuroDerm’s Parkinson’s medication is delivered through a waist-worn pump as compared to other methods delivered orally. As a result of the study’s conclusions, NeuroDerm’s share price doubled, reaching a record high of $14.12 and giving the company a market valuation of $231 million.